GSK Stock Recent News

Glaxo (GSK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PHILADELPHIA--(BUSINESS WIRE)-- #Adolescents--GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis.

GSK plc (NYSE:GSK ) Q1 2025 Earnings Conference Call April 30, 2025 7:00 AM ET Company Participants Constantin Fest - Head of IR Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Julie Brown - CFO David Redfern - President Corporate Development Tony Wood - Chief Scientific Officer Conference Call Participants James Gordon - JP Morgan Kerry Holford - Berenberg Jo Walton - UBS Graham Parry - Bank of America Simon Baker - Redburn Rajan Sharma - Goldman Sachs Sarita Kapila - Morgan Stanley Constantin Fest Ladies and gentlemen, a very warm welcome to this GSK Q1 2025 Results Call. My name is Constantin Fest, new head of IR at GSK, and I'm delighted to be joined today by Emma Walmsley, Luke Miels and Julie Brown.

GSK stock jumped early Wednesday after the drugmaker reported adjusted earnings of $1.20 per share on $10.06 billion in first-quarter sales.

U.S.-listed shares of GSK (GSK) are gaining in premarket trading Wednesday after the British pharma giant posted better-than-expected first-quarter results and said it was "well positioned" should the Trump administration imposes tariffs against the industry.

GSK (GSK) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.09 per share a year ago.

GSK PLC (LSE:GSK, NYSE:GSK) shares rose 4% on Tuesday, adding £2.6 billion to its market value, after the drugmaker delivered better-than-expected first-quarter results and reiterated full-year guidance. The FTSE 100 group reported core earnings per share of 44.9p, 10% ahead of consensus, thanks to stronger operating leverage and a robust margin of 33.7%.

GSK PLC (LSE:GSK, NYSE:GSK) reported earnings ahead of expectations and kept full-year guidance intact, even though sales of vaccines softened. The FTSE 10-listed drugmaker reported a 6.1% fall in vaccine sales to £2.10 billion, which was almost in line with the $2.11 billion average City forecast.

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

--76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evaluating the safety and efficacy of AL101/GSK4527226 in slowing disease progression in individuals with early Alzheimer's disease (AD).